Achieve Life Sciences, Inc. financial data

Symbol
ACHV on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
22722 29 Th Dr. Se, Suite 100, Seattle, WA
State of incorporation
DE
Fiscal year end
December 31
Former names
ONCOGENEX PHARMACEUTICALS, INC. (to 7/31/2017), SONUS PHARMACEUTICALS INC (to 8/7/2008)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 312 % +64.3%
Debt-to-equity 66.1 % -81.8%
Return On Equity -108 % +82.9%
Return On Assets -65.2 % +52.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.4M shares +62.5%
Common Stock, Shares, Outstanding 34.4M shares +62.5%
Entity Public Float 90.8M USD +92.5%
Common Stock, Value, Issued 103K USD +14.4%
Weighted Average Number of Shares Outstanding, Basic 34.4M shares +62.6%
Weighted Average Number of Shares Outstanding, Diluted 34.4M shares +62.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.6M USD -21%
General and Administrative Expense 13.6M USD +19.4%
Costs and Expenses 31.3M USD -7.3%
Nonoperating Income (Expense) -1.68M USD +9.05%
Net Income (Loss) Attributable to Parent -32.9M USD +7.39%
Earnings Per Share, Basic -1.1 USD/shares +46.1%
Earnings Per Share, Diluted -1.1 USD/shares +46.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.54M USD -52.1%
Cash, Cash Equivalents, and Short-term Investments 42.9M USD
Assets, Current 45.5M USD +108%
Property, Plant and Equipment, Net 13K USD +225%
Operating Lease, Right-of-Use Asset 20K USD -75%
Goodwill 1.03M USD 0%
Assets 47.9M USD +96.9%
Accounts Payable, Current 1.01M USD +58.5%
Employee-related Liabilities, Current 2.34M USD +37.7%
Liabilities, Current 6.72M USD +64.5%
Operating Lease, Liability, Noncurrent 6K USD -91.3%
Liabilities 16.5M USD -18.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 75K USD +1775%
Retained Earnings (Accumulated Deficit) -193M USD -20.6%
Stockholders' Equity Attributable to Parent 31.4M USD +677%
Liabilities and Equity 47.9M USD +96.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.29M USD +36.3%
Net Cash Provided by (Used in) Financing Activities 56.1M USD +119283%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 34.4M shares +62.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.8M USD
Deferred Tax Assets, Valuation Allowance 73.2M USD +11.7%
Deferred Tax Assets, Gross 73.6M USD +11.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12.4M USD -74.9%
Property, Plant and Equipment, Gross 256K USD -15.5%
Operating Lease, Liability, Current 22K USD -63.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 48.9M USD +12.6%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 761K USD 0%
Operating Lease, Payments 61K USD +7.02%
Amortization of Intangible Assets 200K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 346K USD -12%
Interest Expense 2.77M USD +6.01%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%